Study of imlunestrant plus abemaciclib before surgery for ER+/HER2- breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs (imlunestrant and abemaciclib) given before surgery for a type of breast cancer that is hormone-receptor positive and HER2 negative. The goal is to see if this treatment shrinks the tumor enough to improve surgery outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and 75 years old.
- Your breast tumor is larger than 1 cm and has been confirmed as ER-positive (at least 50% of cells) and HER2-negative.
- Your cancer is early stage (not spread to distant organs) and you are willing and able to have breast surgery after the study treatment.
- You have good organ function (kidney, liver, blood counts, and heart) as measured by standard tests.
- You agree to use effective contraception if you could become pregnant, and if premenopausal you will take medication to suppress ovarian function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy before surgery for people with high-risk, hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors more effectively than chemotherapy alone.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests if adding abemaciclib (a targeted pill) to standard chemotherapy before surgery can shrink HR+/HER2- breast cancer and allow less extensive surgery. It also aims to see if a genetic test (Oncotype DX) can help guide treatment decisions.
This trial combines a short course of radiation before surgery with two oral medications (abemaciclib and letrozole) to treat early-stage, hormone-sensitive breast cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of two oral medications (abemaciclib and giredestrant) given before surgery to women with a common type of early breast cancer (hormone receptor-positive, HER2-negative). The goal is to see if this treatment can shrink the tumor before surgery.
This trial studies how the immune system and other body signals in blood and tumor tissue relate to how well abemaciclib works before breast cancer surgery. The goal is to learn who benefits most from this medicine and why.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.